Pacific Biosciences of California (PACB) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $40.0M, up 11% sequentially but down from $55.7M year-over-year, with instrument revenue declining and consumables and service revenue increasing.

• New product launches (SPRQ chemistry, Vega sequencer) expanded the addressable market, increased throughput, and reduced sequencing costs.

• Focused on cost reduction, cash burn management, and strengthening the balance sheet, including a major convertible debt exchange with SoftBank.

• Net loss narrowed to $60.7M from $66.9M year-over-year; non-GAAP net loss was $46.0M versus $67.9M.

• Committed to achieving cash flow positivity by end of 2026.

Financial highlights

• Q3 2024 revenue was $40.0M, down from $55.7M in Q3 2023; consumables revenue grew 10% year-over-year to $18.5M.

• Instrument revenue fell 52% year-over-year to $16.8M due to lower Revio shipments.

• Non-GAAP gross margin was 33%, with non-GAAP gross profit of $13.0M.

• Non-GAAP net loss was $46.0M ($0.17/share), improved from $67.9M ($0.27/share) year-over-year.

• Cash, cash equivalents, and investments totaled $471M at quarter-end.

Outlook and guidance

• Q4 2024 revenue expected to be flat to slightly up from Q3; full-year revenue below prior $170M estimate.

• Full-year non-GAAP gross margin expected between 34% and 35%.

• Full-year non-GAAP operating expenses guided to $285–$290M, with further declines expected in 2025.

• Committed to achieving cash flow positivity by end of 2026.

• Revenue growth and margin expansion anticipated in 2025 and beyond, driven by new products and cost improvements.